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Vaccination with a Human Papillomavirus (HPV)-16/18  
AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 
10–14 Years
The human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine has been 
demonstrated to be highly efficacious and immunogenic with a favorable safety profile. 
This study assessed the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted 
vaccine in healthy Korean girls aged 10–14 yr. This multi-center, observer-blind trial 
randomly assigned 321 healthy girls to receive three doses (0, 1, 6-month schedule) of HPV-
16/18 AS04-adjuvanted vaccine or hepatitis A vaccine. Immunogenicity against vaccine 
antigens was assessed one month post-Dose 3. Solicited and unsolicited adverse events 
(AEs) and serious AEs (SAEs) were recorded. In the according-to-protocol analysis, all 
initially seronegative subjects vaccinated with the HPV-16/18 AS04-adjuvanted vaccine 
had seroconverted at Month 7, with a peak geometric mean titer (GMT) that was 600-fold 
higher than the natural infection titer of 29.8 EU/mL for HPV-16 and a peak GMT that was 
400-fold higher than the natural infection titer of 22.6 EU/mL for HPV-18. The vaccine was 
well tolerated with no increase in reactogenicity with subsequent doses and no reports of 
vaccine-related SAEs. In conclusion, the HPV-16/18 AS04-adjuvanted vaccine is shown to 
be highly immunogenic and generally well-tolerated in Korean girls aged 10–14 yr. 
Key Words: Human papillomavirus; HPV-16/18; Uterine Cervical Neoplasms; AS04-
adjuvanted; Prophylactic Vaccine; VLP; Immunogenicity; Safety; Adolescent
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INTRODUCTION
Cervical cancer is the second most common cancer affecting 
women worldwide and also an important complication of geni-
tal HPV infection; approximately 500,000 women are diagnosed 
with this type of cancer, and around 270,000 women die due to 
it each year (1). In Korea, cervical cancer is the 5th most com-
mon female cancer with 4,949 reported cases in 2002 (2) and 
the 5th leading cause of death among Korean women (3) with 
new cases of cervical cancer accounting for 9.8% of female can-
cers (4). The overall age-standardized incidence rate of cervical 
cancer from 1999–2002 was 15.1 per 100,000 women (5). 
 Persistent infection with genital HPV types 16 and 18 is asso-
ciated with a greatly increased risk for subsequent development 
of invasive cervical cancer (ICC) (6, 7). Data from a meta-analy-
sis study on the overall and type-specific HPV prevalence in 
13,842 Korean women showed that in ICC, HPV types 16 and 18 
accounted for 65.1% of cases (8). HPV-16 and 18, and HPV-45 
are the most commonly detected HPV types in women with cer-
vical adenocarcinoma and squamous cell carcinoma (SCC) (9). 
It is suggested that greater than 50% of all sexually active wom-
en will be exposed to at least one genital HPV at some point in 
their life (10). In a meta-analysis of a systematic literature review, 
young women aged below 25 yr were found to have the highest 
prevalence of HPV infection (11), whereas persistent HPV infec-
tions became more prominent with increasing age (12). HPV 
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infections are seen to be the highest in adolescent populations 
(13) and most are acquired soon after initiation of sexual activi-
ty. Considering the natural history of HPV infection, the optimal 
target age for immunization are pre-adolescent girls in order to 
provide them with protection before sexual debut. 
 The HPV-16/18 AS04-adjuvanted vaccine is now licensed in 
over 90 countries worldwide and has been shown to be highly 
efficacious, immunogenic and generally well-tolerated in pre-
vious global studies (14, 15). In addition, the vaccine was also 
highly efficacious in the prevention of incident and persistent 
HPV-16/18 infections and in the maintenance of cross-protec-
tion against incident infections caused by HPV-31 and HPV-45 
for at least 6.4 yr of follow-up (16). Vaccine-induced immune 
responses in young female adolescents were approximately two-
fold higher than those elicited in women aged 15–25 yr (17). 
Though there are several studies on the HPV-16/18 AS04-adju-
vanted vaccine worldwide (14–17), there has been previously 
no data of this vaccine in the Korean population. 
 Thus, the present phase III study was performed to evaluate 
the immunogenicity and safety of the HPV-16/18 AS04-adju-
vanted vaccine in Korean girls aged 10–14 yr. 
 
MATERIALS AND METHODS
Study population 
A total of 321 healthy pre-adolescents and adolescents females 
10–14 yr were enrolled in the study (Clinical trial Number - NCT-
00290277) from eight centers in Korea between November 2005 
and August 2006. 
 The study protocol, amendments and consent forms were 
approved by the Institutional Review Board (KCMC05MT092, 
05-40, H-0509-509-157, 2005-0258-12, 05-36, 2005-09-013-034, 
2007-27, 2005-269) of each study center. The study was conduct-
ed in accordance with Good Clinical Practice and all applicable 
local regulatory requirements and the Declaration of Helsinki. 
Written informed assent was obtained from each subject, and 
written informed consent was obtained from each subject’s par-
ent/legally acceptable representative before entry into the study.
 Subjects were required to be healthy, not taking any other in-
vestigational products or immune-modifying drugs, not preg-
nant or planning to become pregnant, or breastfeeding during 
the study. Subjects with child bearing potential were required 
either to be taking effective contraception or abstinent from 
sexual relations. Pregnancy tests were conducted prior to each 
vaccination. Subjects were not to have received previous vacci-
nation with a HPV vaccine.
Study objectives 
Primary objective: To assess the immunogenicity of the HPV-
16/18 AS04-adjuvanted vaccine one month after the third vac-
cine dose. 
 Secondary objectives: To evaluate vaccine reactogenicity and 
safety for 30 days after each vaccine dose and throughout the 
study period.
Study vaccines and study design
The study vaccine (CervarixTM, GlaxoSmithKline Biologicals, 
Rixensart, Belgium), was an HPV-16/18 L1 (L1 - structural pro-
tein of HPV) Virus Like Particle (VLP) vaccine that contained 
HPV-16 L1 protein (20 μg), HPV-18 L1 protein (20 μg). The vac-
cine was adjuvanted with AS04 (50 μg of 3-O-desacyl-4´-mono-
phosphoryl lipid A [MPL] and aluminum, Al[OH]3 500 μg) (17, 18). 
 The control used in this study was hepatitis A virus vaccine 
(HAV-HavrixTM, GlaxoSmithKline Biologicals, Rixensart, Bel-
gium) containing 360 enzyme-linked immunosorbent assay 
(ELISA) units - EU of inactivated hepatitis A viral antigen and 
250 μg of aluminum (Al[OH]3). This vaccine was used rather than 
an aluminum placebo to provide a benefit to participants.
 Participants were randomly allocated to two groups in a 1:1 
ratio using an internet-based randomization system, to receive 
either HPV-16/18 or HAV vaccine. Vaccines were supplied in 
individual 0.5 mL pre-filled syringes and administered into the 
deltoid muscle according to a 0, 1, 6 month schedule. Due to dif-
ferences in the visual appearance of the HPV-16/18 L1 VLP AS04 
vaccine and the control vaccine, the syringes were prepared and 
administered by qualified medical personnel not otherwise in-
volved in study conduct or in the assessment of symptoms, so 
treatment allocation remained blinded.
 During the initial stages of the trial, some vaccine doses were 
suspected to have been accidentally exposed to freezing temper-
atures during vaccine shipment to trial sites and were injected to 
some subjects (HPV-16/18 group, 18; control group, 17) as their 
first dose. The extent of a possible impact of vaccination with 
these vaccines on the immunogenicity study endpoints was eval-
uated and statistical analyses revealed no impact on the validity 
of results.
Serological evaluation
Blood samples were collected from subjects at baseline (before 
vaccination) and at Month 7 (one month after the third vaccine 
dose) to evaluate immunogenicity. Antibodies against HPV-16 
and HPV-18 were evaluated in subjects from both groups using 
a type-specific ELISA as reported elsewhere (18). HAV-specific 
antibodies were evaluated in subjects from both groups using a 
commercially available ELISA assay (Enzygnost®, Behring Diag-
nostics, Malburg, Germany). 
Safety evaluation 
In the first 30-min post-vaccination period, subjects were ob-
served for any adverse events (AEs) following which they were 
given diary cards to record observations up to the following visit. 
These diary cards were designed to record information on specif-
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ic solicited local AEs (injection site pain, redness and swelling), 
systemic AEs (fever, headache, fatigue, gastrointestinal symp-
toms, arthralgia, myalgia, rash and urticaria) and any other un-
solicited AEs. Solicited AEs were recorded for 7 days (days 0–6) 
after each vaccination. The intensity of all solicited AEs was grad-
ed on a 3-point scale (Table 1). Urticaria or rash that appeared 
within 30 min of each vaccine dose was also documented by the 
investigator. Unsolicited signs and symptoms were reported with-
in 30 days (days 0–29) after each dose. Any changes in hemato-
logic and biochemistry values were assessed in blood samples 
taken from subjects at baseline and at Month 7. Serious adverse 
events (SAEs), pregnancies, medically significant conditions and 
new onset of chronic diseases were also collected throughout 
the study. Medically significant conditions were defined as con-
ditions that prompted emergency room or physician visits that 
were not related to common diseases or routine visits for physi-
cal examination or vaccination, or SAEs that were not related to 
common diseases, occurring during the entire study period.
Statistical analysis
Statistical analyses were performed using Statistical Analysis 
System (SAS) 8.2 (SAS Institute, Cary, NC, USA) and Proc StatX-
act-5 (Cytel Inc, Cambridge, MA, USA) and all sample size cal-
culations were performed using nQuery 4.0.
 The sample size was calculated to demonstrate with at least 
90% power that seroconversion rates for each vaccine antigen 
after the third dose was not less than 90%.
 The primary immunogenicity analyses were done on the ac-
cording-to-protocol (ATP) cohort for immunogenicity, includ-
ing all subjects meeting eligibility criteria, complying with the 
procedures defined in the protocol, and for whom assay results 
were available for antibodies against at least one study vaccine 
antigen component after vaccination.
 Immunogenicity prior to the first vaccination and at post-dose 
3 was evaluated for each vaccine antigen. Geometric mean an-
tibody titers (GMTs), seropositivity and seroconversion rates 
with their 95% confidence intervals (CIs) were calculated. 
 The primary analysis for reactogenicity and safety was based 
on the total vaccinated cohort and included all vaccinated sub-
jects, with at least one vaccine administration documented for 
the analysis of safety and with immunogenicity data available 
for the analysis of immunogenicity.
 The two-sided standardized asymptotic 95% CI for the differ-
ence in SAE rates was computed. The comparison was done by 
subject, considering all SAEs at the same level and then consid-
ering individual SAEs. 
 Incidence rates of solicited AEs (7-day follow-up period) and 
unsolicited symptoms (30-day follow-up period) were tabulat-
ed with exact 95% CIs over all vaccine doses and for each treat-
ment group. 
 Separate immunogenicity and safety analyses were performed 
for subjects who had received as their first dose a vaccine which 
may have been temperature-deviated. 
Table 1. Solicited AEs reported in the 7-day post-vaccination follow-up period, overall per-dose (total vaccinated cohort)
Solicited adverse 
   event
Type
HPV-16/18 group (n=474) Control group (n=483)
No. % 95% CI No. % 95% CI
Pain Any
Grade 3
286
    3
60.3
  0.6
55.8-64.8
0.1-1.8
147
  0
30.4
  0.0
26.4-34.8
0.0-0.8
Redness Any
>50 mm
119
    5
25.1
  1.1
21.3-29.3
0.3-2.4
54
  0
11.2
  0.0
8.5-14.3
0.0-0.8
Swelling Any
>50 mm
  99
    3
20.9
  0.6
17.3-24.8
0.1-1.8
27
  0
  5.6
  0.0
3.7-8.0
0.0-0.8
Arthralgia Any
Grade 3
  26
    0
  5.5
  0.0
3.6-7.9
0.0-0.8
18
  0
  3.7
  0.0
2.2-5.8
0.0-0.8
Fatigue Any
Grade 3
  90
    1
19.0
  0.2
15.6-22.8
0.0-1.2
87
  2
18.0
  0.4
14.7-21.7
0.1-1.5
Fever 
   (Axillary route)
Any
>39.0°C
  13
    1
  2.7
  0.2
1.5-4.6
0.0-1.2
  7
  0
  1.4
  0.0
0.6-3.0
0.0-0.8
Gastrointestinal
   symptoms
Any
Grade 3
  24
0
  5.1
  0.0
3.3-7.4
0.0-0.8
33
  0
  6.8
  0.0
4.7-9.5
0.0-0.8
Headache Any
Grade 3
62
0
13.1
  0.0
10.2-16.5
0.0-0.8
76
  1
15.7
  0.2
12.6-19.3
0.0-1.1
Myalgia Any
Grade 3
79
0
16.7
  0.0
13.4-20.3
0.0-0.8
40
  0
  8.3
  0.0
6.0-11.1
0.0-0.8
Rash Any
Grade 3
19
0
  4.0
  0.0
2.4-6.2
0.0-0.8
  9
  0
  1.9
  0.0
0.9-3.5
0.0-0.8
Urticaria Any
Grade 3
5
0
  1.1
  0.0
0.3-2.4
0.0-0.8
  5
  1
  1.0
  0.2
0.3-2.4
0.0-1.1
n, Number of documented doses (diary cards returned); No. (%), Number (percentage) of doses followed by at least one type of solicited symptom; 95% CI, Exact 95% confidence 
interval; Grade 3 Pain, Pain that prevented normal activity; Grade 3 Redness/swelling, Injection site redness/swelling >50 mm; Grade 3 Arthralgia/Fatigue/Gastrointestinal 
symptoms/Headache/Myalgia/\Rash, Symptoms prevented normal activity; Grade 3 Fever, Fever >39.0°C; Grade 3 Urticaria, Urticaria distributed on at least 4 body areas.
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RESULTS
Study compliance was high, with ≥98.8% of subjects in the HPV-
16/18 group and all subjects in the control group receiving all 
three vaccine doses.
 Of the 321 subjects enrolled and vaccinated (HPV-16/18 group, 
160; control group, 161), 319 (158 in the HPV-16/18 group and 
161 in the control group) completed the study. The parents of 
two subjects (both in the HPV-16/18 group) withdrew their con-
sent; none of which were due to AEs. The mean age of subjects 
in the total vaccinated cohort at the time of the first dose was 
11.9 yr (standard deviation [SD] ±1.41). Both groups and analy-
sis cohorts were well balanced with respect to baseline demo-
graphic characteristics, such as age and race. 
 A total of 248 subjects met the eligibility criteria for the ATP 
immunogenicity analysis (Fig. 1).
Immunogenicity (ATP cohort)
Immunogenicity analyses were stratified by serology status at 
baseline and seroconversion rate for each HPV antigen was cal-
culated in subjects who were seronegative for the HPV-16 or 
HPV-18 antigen. The majority of subjects (up to 89.9% in each 
group) were seronegative for both HPV-16 and HPV-18 antigens. 
About 10% of subjects in the HPV-16/18 group were seroposi-
tive at baseline for either HPV-16 or HPV-18 antigens. 
 In the HPV-16/18 group, seroconversion rates for HPV-16 
and HPV-18 antigens in initially seronegative girls were 100% at 
Month 7. The geometric mean titer (GMT) was 19619.8 EU/mL 
(95% CI: 17188.6-22394.8) for HPV-16, and 9894.5 EU/mL (95% 
CI: 8674.1-11286.6) for HPV-18. All initially seropositive girls re-
mained seropositive for both antigens at Month 7 with marked-
ly higher GMTs than those observed before vaccination and 
were similar to GMTs in initially seronegative girls (Table 2). 
 In the control group, the seroconversion rate for anti-HAV an-
tibody at Month 7 was 100% in initially seronegative girls. Anti-
HAV GMT was also high at Month 7. Immunogenicity analyses 
on the total vaccinated cohort were consistent with the results 
of the ATP cohort analyses. Immunogenicity analyses conduct-
ed in girls who had received a vaccine which may have been 
temperature-deviated did not show any impact.
Enrolled and Vaccinated (Total Vaccinated Cohort)
N=321
n=160
HPV-16/18 Group
Enrolm
ent
safety evaluation
Im
m
unogenicity evaluation
n=158 completed the study
Reasons for not completing the study:
Consent withdrawal not due to AE (2)
n=126
ATP cohort (safety analysis)
34 excluded:
∙ Protocol forbidden vaccine administered (6)
∙ Randomization procedure for treatment allocation of subjects
    not followed (manual randomization) (11) 
∙ Administration of first vaccine dose suspected to have been
    accidentally temperature-deviated during shipment to study 
    sites (17)*
n=120
ATP cohort (immunogenicity analysis)
6 excluded:
∙ Protocol violation (3)
∙ Non-compliance with vaccine schedule (2)
∙ Serological data missing (no post-dose 3 blood sample) (1)
n=132
ATP cohort (safety analysis)
29 excluded:
∙ Protocol forbidden vaccine administered (2)
∙ Randomization procedure for treatment allocation of subjects
    not followed (manual randomization) (10) 
∙ Administration of first vaccine dose suspected to have been
    accidentally temperature-deviated during shipment to study 
    sites (17)
n=128
ATP cohort (immunogenicity analysis)
4 excluded:
∙ Protocol violation (1)
∙ Non-compliance with vaccine schedule (2)
∙ Non-compliance with blood sampling schedule (1)
n=161
Control Group
n=161 completed the study
No withdrawals from the study
Fig. 1. Trial profile. This study recruited and randomized 321 healthy Korean girls aged 10-14 yr and they received at least one dose of the HPV-16/18 AS04-adjuvanted 
vaccine or the hepatitis A vaccine. A total of 319 girls completed the study. The parents of two subjects in the HPV-16/18 group withdrew their consent which was not due to 
adverse events. Eligibility criterion for the ATP safety analysis was met for 258 participants and after further exclusions 248 subjects met the eligibility criteria for the ATP 
immunogenicity analysis.
*, 18 subjects in total, but one subject was already excluded for administration of protocol-forbidden vaccine.
n, Number of subjects.
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Reactogenicity and safety (Total vaccinated cohort)
Compliance in returning diary cards was high (>99% in the two 
groups). Subjects from the HPV-16/18 group reported more in-
jection site symptoms (pain, redness and swelling) than the con-
trol group. The most commonly reported symptom was injec-
tion site pain (Table 2). Local symptoms tended to be transient, 
lasting no longer than 4–5 days. These group differences in injec-
tion site reactions however had no impact on compliance with 
completion of the vaccination course. The frequency of local 
symptoms with grade 3 intensity following vaccine doses re-
mained low in the HPV-16/18 group (up to 2.3% overall). None 
of the subjects in the control group reported any local symptoms 
of grade 3 intensity. No urticaria or rash was reported in the 30-
min post-vaccination observation period. The incidence of sys-
temic reactions, was generally comparable between groups, with 
the exception of myalgia reported more frequently in the HPV-
16/18 group. Overall, grade 3 systemic reactions were reported 
infrequently in both groups, with no reports of grade 3 myalgia 
in either group. Neither group showed an increase in reactoge-
nicity for local and general AEs with increasing number of doses. 
 Unsolicited AEs occurred with similar frequencies in both 
groups. The most frequently reported unsolicited AEs in both 
groups were infections such as upper respiratory tract infections, 
nasopharyngitis and rhinitis, and dizziness. A minority of the 
unsolicited symptoms in both groups (2.1% of doses in the HPV-
16/18 group and 0.4% of doses in the control group) were con-
sidered by the reporting investigator as possibly vaccine related. 
 The onset of chronic diseases that were identified during the 
study were contact dermatitis and urticaria (each symptom re-
ported by two subjects in the HPV-16/18 group) and atopic der-
matitis (one subject in the HPV-16/18 group and two subjects 
in the control group).
 One vaccine recipient in the control group reported a SAE 
(gastroenteritis) after the second dose, that required hospitaliza-
tion. This SAE was judged as not being vaccine-related, resolved 
without sequelae and the subject completed the vaccination 
course. No pregnancies were reported. The occurrence of med-
ically significant conditions reported during the study period was 
similar in both groups (HPV-16/18 group: 6.9%; control group: 
6.2%). No clinically significant modification of hematological or 
biochemical parameters was observed in girls when these pa-
rameters were assessed at study entry and at Month 7. 
 Reactogenicity and safety results in girls who had received as 
their first vaccination a vaccine that may have been tempera-
ture-deviated, were similar to that of girls in the per-protocol 
cohort. 
DISCUSSION
This study was conducted in a cohort of pre-pubertal girls and 
young adolescents in Korea. An online survey of behavioral health 
factors in 80,000 Korean adolescents aged 12–17 yr suggests that 
Table 2. Seroconversion/seropositivity rates and GMTs one month after vaccination (ATP cohort for immunogenicity)
Pre-
vacc
status
Timing
HPV-16/18 group Control group
No.
Seroconversion/
Seropositivity
GMT
No. 
Seroconversion/
Seropositivity
GMT
Rate % 95% CI Value 95% CI Rate % 95% CI Value 95% CI
Anti-HPV-16  
   ≥8 EU/mL
S –
S+
Total
PRE
PIII (M7)
PRE
PIII (M7)
PRE
PIII (M7)
112
112
7.0
7.0
119
119
0.0
100
100
100
5.9
100
0.0-3.2
96.8-100
59-100
59-100
2.4-11.7
96.9-100
4.0
19619.8
24.7
20778.6
4.5
19686.1
4.0-4.0
17188.6-22394.8
15.1-40.1
13383.8-32259.2
4.1-4.8
17356.8-22328.1
120
120
8
8
128
128
0.0
6.7
100
75.0
6.3
10.9
0.0-3.0
2.9-12.7
63.1-100
34.9-96.8
2.7-11.9
6.1-17.7
4.0
4.8
27.4
34.4
4.5
5.4
4.0-4.0
4.2-5.5
11-68.1
3.7-316.5
4.1-5.0
4.5-6.6
Anti-HPV-18  
   ≥7 EU/mL
S –
S+
Total
PRE
PIII (M7)
PRE
PIII (M7)
PRE
PIII (M7)
115
115
5
5
120
120
0.0
100
100
100
4.2
100
0.0-3.2
96.8-100
47.8-100
47.8-100
1.4-9.5
97-100
3.5
9894.5
10.8
9097.1
3.7
9859.9
3.5-3.5
8674.1-11286.6
6.7-17.5
6155.6-13444.0
3.5-3.8
8687.9-11189.9
119
119
9
9
128
128
0.0
7.6
100
66.7
7.0
11.7
0.0-3.1
3.5-13.9
66.4-100
29.9-92.5
3.3-12.9
6.7-18.6
3.5
4.7
19.5
10.1
3.9
5.0
3.5-3.5
3.8-5.9
11.1-34.0
4.4-23.6
3.6-4.3
4.0-6.1
Anti-HAV  
   ≥15 mIU/mL
S –
S+
Total
PRE
PIII (M7)
PRE
PIII (M7)
PRE
PIII (M7)
105
105
15
15
120
120
0.0
10.5
100
73.3
12.5
18.3
0.0-3.5
5.3-18.0
78.2-100
44.9-92.2
7.2-19.8
11.9-26.4
7.5
8.9
46.5
84.9
9.4
11.8
7.5-7.5
7.9-10.1
26.1-82.9
28.2-255.5
8.3-10.7
9.6-14.6
115
115
13
13
128
128
0.0
100
100
100
10.2
100
0.0-3.2
96.8-100
75.3-100
75.3-100
5.5-16.7
97.2-100
7.5
1828.0
69.4
3363.6
9.4
1944.8
7.5-7.5
1557.6-2145.3
18.5-259.8
1801.6-6279.6
8.0-11.1
1661.7-2276.1
Pre-vacc Status: Serology status prior to vaccination.
Seroconversion was defined as the appearance of antibodies in the serum of initially seronegative subjects with a titer greater than or equal to the assay cut-off value.
Seropositivity was defined as a titer greater ≥the assay cut-off value established at 8 ELISA units (EU)/mL for HPV-16, 7 EU/mL for HPV-18 and 15 mIU/mL for HAV. GMT, 
Geometric Mean Titer calculated on all subjects.
No., Number of subjects with results; Rate %, Percentage of subjects with titers greater than or equal to the assay cut-off value; S –, Seronegative subjects (antibody titers 
lesser than the assay cut-off value) prior to vaccination; S+, Seropositive subjects (antibody titers greater than or equal to the assay cut-off value) prior to vaccination; Pre, Pre-
Vaccination; PIII(M7), Post Dose 3, Month 7.
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sexual onset occurs at a relatively early age of 14 yr (19) as com-
pared to that reported in previous data (20). Young age at onset 
of sexual activity was identified as one of the significant risk fac-
tors for HPV infection in two HPV prevalence surveys conduct-
ed in Busan, Korea (20, 21). Due to the lifestyle and sexual be-
havior of Korean women, the prevalence of HPV infection is in-
creasing, and cervical cancer remains a major public health con-
cern in Korean women. Hence, vaccination against the most 
prevalent HPV types 16 and 18 has the potential to significantly 
reduce HPV infection and its consequences in Korea (22).
 In our study, all initially seronegative subjects seroconverted 
to both antigens. At Month 7, GMTs were over 400-fold higher 
than natural infection titers for both antigens (14). Initially sero-
positive subjects remained seropositive and elicited a marked 
increase in GMTs from those seen before vaccination, which 
indicates that prior exposure to natural HPV infection does not 
affect the immune response generated by the HPV-16/18 AS04-
adjuvanted vaccine. The high GMT levels generated in initially 
seropositive women are important as there is no clear evidence 
that natural immune response is reliably protective against re-
infection. 
 The magnitude of antibody titers or GMTs achieved in the 
current study cohort is in line with another study that evaluated 
the vaccine in European adolescent girls aged 10–14 yr (17). 
GMTs elicited in this young age group were twice as high com-
pared to those in women aged 15–25 yr at Month 7. The vaccine 
has been shown to induce high and sustained anti-HPV-16 and 
anti-HPV-18 antibody levels and shown to be efficacious against 
CIN2+ and persistent infections associated with HPV-16/18 up 
to 6.4 yr after first vaccination in women aged 15–25 yr (16). The 
final event-driven analysis of a large multinational Phase III trial 
in women aged 15–25 yr also showed that the HPV-16/18 AS04-
adjuvanted vaccine was highly efficacious against CIN2+ lesions 
associated with HPV-16 and HPV-18 as well as those associated 
with non-vaccine oncogenic types HPV-31, HPV-33 and HPV-
45 (23). 
 Transudation of high vaccine-induced serum IgG antibodies 
into cervical secretions is likely to be an important mechanism 
of protection against cervical HPV infection (24, 25). Apart from 
the HPV-16/18 AS04-adjuvanted vaccine inducing a robust and 
persistent immune response in the serum, high levels of anti-
bodies were detected in cervicovaginal secretions (15, 26) and 
could therefore play a prominent role in local immunity to bind 
to HPV virus particles (25). Applying the antibody transudation 
theory, it can be speculated that the higher the systemic immune 
response elicited by a parenterally administered vaccine, the 
higher the level of transudated antibodies at the site of infection 
and as consequence, the better the expected protection and the 
longer protective duration. This assumption can be extended to 
the high levels of IgG responses elicited by vaccination in the 
target age group (10–14 yr) in our study. With the established 
efficacy in women aged 15–25 yr, it can be extrapolated that the 
protection in young adolescents will last for at least as long as 
the sustained efficacy observed in previously published results 
(16, 27, 28). An advantage of the HPV-16/18 vaccine used in the 
study was the unique AS04 adjuvant in its formulation. In a pre-
vious study, the immune response induced by this AS04 adju-
vant formulation was observed as being higher to that induced 
by the same antigens adjuvanted with aluminum alone (18).
 In our study, the safety data in young Korean adolescents 
showed that the HPV-16/18 AS04-adjuvanted vaccine was gen-
erally well tolerated (good compliance with the 3-dose vaccina-
tion schedule) and had an acceptable safety profile. This is in 
line with the results of a pooled safety analysis from 11 Phase II/
III trials with the HPV-16/18 AS04-adjuvanted vaccine which 
showed a favorable safety profile in women of all ages (29). The 
benefit of prophylactic HPV vaccination in these young girls is 
underscored, as vaccination in this age group generates a robust 
immune response exceeding that seen in older women. A strong 
immune response is of particular importance for young adoles-
cents to translate into sustained protection (17) so they are still 
protected during their peak exposure to natural infection (30). 
 The younger age of sexual debut among Korean adolescents 
and girls has resulted in an increased occurrence of HPV infec-
tion in this population (19-21). Therefore, prevention at the ear-
liest stage is of prime importance. WHO recommends vaccina-
tion of young women prior to their sexual debut and the inclu-
sion of routine HPV vaccination in a country’s national immu-
nization program. 
 In conclusion, this study evaluated the HPV-16/18 AS04-ad-
juvanted vaccine for the first time in Korean girls aged 10–14 yr, 
and confirmed that it is highly immunogenic and well tolerated 
in this population. With cervical cancer posing such a huge phys-
ical, psychological, social and financial burden on women in 
Korea, prophylactic HPV vaccination could be integrated into 
the existent vaccination programs for adolescents to help reduce 
the high disease burden of cervical cancer.
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